MSD

News

NICE delivers more good news for cervical cancer patients

Hundreds of women with locally advanced cervical cancer are to be offered MSD's Keytruda on the NHS in England, thanks to new NICE guidance.

News

MSD's TL1A drug tulisokibart delivers in pivotal IBD trial

MSD's tulisokibart has become the first anti-TL1A antibody to help patients with ulcerative colitis achieve clinical remission in a phase 3 trial.

News

MSD takes on Pfizer's Prevnar with new Capvaxive approval

MSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of Capvaxive in vulnerable children aged two to 17.

News

MSD steps out with Protillion in $510m+ AI shindig

MSD has teamed up with Protillion Bio in a deal worth more than $510m, focusing on using the AI start-up's lab-in-the-loop platform for drug discovery

News

FDA starts kicks off review of Gilead's weekly HIV pill

The FDA is due to deliver a verdict in February on Gilead's once-weekly pill for HIV PrEP, which could expand the options available to patients.

News

MSD's Sac-TMT delivers in first phase 3 readout

MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.

NICE delivers more good news for cervical cancer patients

MSD's TL1A drug tulisokibart delivers in pivotal IBD trial

MSD takes on Pfizer's Prevnar with new Capvaxive approval

MSD steps out with Protillion in $510m+ AI shindig

FDA starts kicks off review of Gilead's weekly HIV pill

MSD's Sac-TMT delivers in first phase 3 readout

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

Discover a new era of healthcare panel engagement: Grounded ...

MSD

Editor's Picks